Trauma

3
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

DS
Daiichi SankyoChina - Shanghai
1 program
1
Transdermal PatchPhase 31 trial
Active Trials
NCT02616068Completed242Est. Dec 2016
CSL Behring
CSL BehringIL - Bradley
1 program
1
FibrinogenPhase 21 trial
Active Trials
NCT02344069Completed40Est. Apr 2017
KB
Kuros BiosciencesSwitzerland - Schlieren
1 program
1
open fracture reductionPhase 21 trial
Active Trials
NCT00533793CompletedEst. May 2011
Rhythm Pharmaceuticals
1 program
Registry AutoLog Lipid Removal and Blood Component CharacterizationN/A1 trial
Active Trials
NCT01565967Completed199Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daiichi SankyoTransdermal Patch
CSL BehringFibrinogen
Kuros Biosciencesopen fracture reduction
Rhythm PharmaceuticalsRegistry AutoLog Lipid Removal and Blood Component Characterization

Clinical Trials (4)

Total enrollment: 481 patients across 4 trials

NCT02616068Daiichi SankyoTransdermal Patch

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

Start: Oct 2015Est. completion: Dec 2016242 patients
Phase 3Completed

Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage

Start: Feb 2015Est. completion: Apr 201740 patients
Phase 2Completed
NCT00533793Kuros Biosciencesopen fracture reduction

Adjunctive Therapy to Treat Tibial Shaft Fractures

Start: Apr 2007Est. completion: May 2011
Phase 2Completed
NCT01565967Rhythm PharmaceuticalsRegistry AutoLog Lipid Removal and Blood Component Characterization

Registry AutoLog Lipid Removal and Blood Component Characterization

Start: Dec 2011Est. completion: Mar 2013199 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space